CRT’s Discovery Laboratories extends alliance with Merck to develop new cancer drugs

Anne Li                        6/30/2017                         anne2001.li@gmail.com


CANCER RESEARCH TECHNOLOGY (CRT) has signed a further deal with Merck, a leading science and technology company, to discover new cancer drugs targeting the Hippo pathway on Thursday. The extension to this alliance follows a successful one-year target validation and drug discovery feasibility partnership between CRT’s Discovery Laboratories (CRT-DL) in London and Cambridge and Merck at Darmstadt in Germany. In conjunction with Cancer Research UK’s network of key academic scientists, led by Dr Nic Tapon and Dr Barry Thompson, based at the Francis Crick Institute in London, the alliance has developed a better understanding of the role of the Hippo pathway in cancer, and how best to drug key targets.


See original article at: https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2017-06-28-crts-discovery-laboratories-extends-alliance-with-merck-to-develop-new-cancer-drugs


Post a comment